NASDAQ:EVGN Evogene (EVGN) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free EVGN Stock Alerts $0.67 +0.02 (+2.88%) (As of 12:03 PM ET) Add Compare Share Share Today's Range$0.64▼$0.6950-Day Range$0.61▼$0.9852-Week Range$0.45▼$1.44Volume27,597 shsAverage Volume167,764 shsMarket Capitalization$27.57 millionP/E RatioN/ADividend YieldN/APrice Target$3.62 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Evogene alerts: Email Address Evogene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside424.2% Upside$3.62 Price TargetShort InterestHealthy0.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector762nd out of 910 stocksAgricultural Chemicals Industry9th out of 10 stocks 3.5 Analyst's Opinion Consensus RatingEvogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvogene has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.21% of the outstanding shares of Evogene have been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently increased by 20.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEvogene does not currently pay a dividend.Dividend GrowthEvogene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVGN. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows5 people have added Evogene to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Evogene is held by insiders.Percentage Held by InstitutionsOnly 10.40% of the stock of Evogene is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Evogene is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evogene is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvogene has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Evogene Stock (NASDAQ:EVGN)Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.Read More EVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVGN Stock News HeadlinesApril 16, 2024 | americanbankingnews.comEvogene (NASDAQ:EVGN) Coverage Initiated at StockNews.comApril 11, 2024 | prnewswire.comBiomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual MeetingApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 2, 2024 | finance.yahoo.comEvogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food IndustryMarch 28, 2024 | prnewswire.comEvogene Announces Filing of Annual Report on Form 20-FMarch 20, 2024 | prnewswire.comEvogene Reports Receipt of Nasdaq Minimum Bid Price NotificationMarch 19, 2024 | prnewswire.comBayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse TestingMarch 8, 2024 | finance.yahoo.comEvogene Ltd. (NASDAQ:EVGN) Q4 2023 Earnings Call TranscriptApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 7, 2024 | investorplace.comEVGN Stock Earnings: Evogene Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | de.investing.comEvogene: EPS übertrifft Schätzungen um 0,01 $ - Umsatz schlechter als erwartetMarch 7, 2024 | finance.yahoo.comEvogene Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | finanznachrichten.deAgPlenus Ltd.: AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel HerbicidesMarch 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from Evogene's earnings reportMarch 6, 2024 | benzinga.comEvogene Earnings PreviewMarch 6, 2024 | finance.yahoo.comAgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel HerbicidesMarch 5, 2024 | prnewswire.comCasterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed VarietiesFebruary 28, 2024 | prnewswire.comLavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement RequirementsFebruary 26, 2024 | finance.yahoo.comEvogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024February 26, 2024 | prnewswire.comEvogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024February 22, 2024 | prnewswire.comAgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive OfficerFebruary 21, 2024 | finanznachrichten.deBayer schwankt, deutliche Gewinnmitnahmen bei Renk, Zweifel um Nvidia und auch bei Super Micro Computer ist die Luft rausFebruary 21, 2024 | finance.yahoo.comAgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control SolutionFebruary 21, 2024 | prnewswire.comAgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control SolutionFebruary 20, 2024 | businesswire.comSyngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-InsecticideFebruary 20, 2024 | prnewswire.comSyngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-InsecticideJanuary 17, 2024 | finanznachrichten.deBiomica Ltd.: Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology DrugSee More Headlines Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/23/2024Next Earnings (Estimated)5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Agricultural chemicals Sub-IndustryN/A Current SymbolNASDAQ:EVGN CUSIPN/A CIK1574565 Webwww.evogene.com Phone(728) 931-1900Fax972-8946-6724Employees142Year FoundedN/APrice Target and Rating Average Stock Price Target$3.62 High Stock Price Target$6.00 Low Stock Price Target$1.85 Potential Upside/Downside+424.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,880,000.00 Net Margins-423.39% Pretax Margin-460.76% Return on Equity-76.93% Return on Assets-45.13% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.95 Sales & Book Value Annual Sales$5.64 million Price / Sales5.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book0.99Miscellaneous Outstanding Shares41,220,000Free Float38,166,000Market Cap$28.44 million OptionableOptionable Beta1.49 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Ofer Haviv CPA (Age 58)CEO & President Comp: $390kDr. Nir Arbel (Age 44)Chief Product Officer Comp: $228kDr. Brian Ember (Age 48)Chief Executive Officer of AgPlenus Ltd Comp: $287kDr. Elran Hillel Haber M.B.A. (Age 44)Ph.D., Chief Executive Officer of Biomica Ltd Comp: $302kMr. Amit Noam Capt. res. (Age 42)Chief Executive Officer of Lavie Bio Ltd. Comp: $136kMr. Yaron Eldad (Age 59)Chief Financial Officer Mr. Mark Kapel (Age 47)Chief Technology Officer Comp: $276kRachel Pomerantz GerberHead of Investor RelationsMr. Sassi Masliah (Age 45)Vice President of Corporate Development Comp: $245kMs. Liat Foigel WejgmanVice President of Human ResourcesMore ExecutivesKey CompetitorsSingular Genomics SystemsNASDAQ:OMICSpruce BiosciencesNASDAQ:SPRBMEDIROM Healthcare TechnologiesNYSE:MRMFemasysNASDAQ:FEMYPrenetics GlobalNASDAQ:PREView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 5,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions EVGN Stock Analysis - Frequently Asked Questions Should I buy or sell Evogene stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EVGN shares. View EVGN analyst ratings or view top-rated stocks. What is Evogene's stock price target for 2024? 3 brokers have issued 12 month price targets for Evogene's stock. Their EVGN share price targets range from $1.85 to $6.00. On average, they anticipate the company's share price to reach $3.62 in the next year. This suggests a possible upside of 424.2% from the stock's current price. View analysts price targets for EVGN or view top-rated stocks among Wall Street analysts. How have EVGN shares performed in 2024? Evogene's stock was trading at $0.84 at the beginning of 2024. Since then, EVGN shares have decreased by 17.9% and is now trading at $0.69. View the best growth stocks for 2024 here. Are investors shorting Evogene? Evogene saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 86,500 shares, an increase of 20.8% from the March 15th total of 71,600 shares. Based on an average daily trading volume, of 173,900 shares, the days-to-cover ratio is presently 0.5 days. View Evogene's Short Interest. When is Evogene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our EVGN earnings forecast. How were Evogene's earnings last quarter? Evogene Ltd. (NASDAQ:EVGN) posted its quarterly earnings data on Thursday, March, 7th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. The biotechnology company had revenue of $0.58 million for the quarter, compared to analyst estimates of $1.73 million. Evogene had a negative trailing twelve-month return on equity of 76.93% and a negative net margin of 423.39%. During the same period in the prior year, the company earned ($0.07) EPS. What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evogene investors own include AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Abbott Laboratories (ABT), Acasti Pharma (ACST) and Akari Therapeutics (AKTX). How do I buy shares of Evogene? Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVGN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
